Systemic reduced‐dose alteplase for diffuse pulmonary thrombi in a COVID‐19 patient

Pulmonary embolism has a high frequency in COVID‐19 patients admitted to the intensive care unit. Low level of fibrinolysis is one of the asserted contributors to a prothrombotic state in COVID‐19. Thrombotic coagulopathy is mostly encountered as diffuse pulmonary thrombi. Diffuse pulmonary microemb...

Descripción completa

Detalles Bibliográficos
Autor principal: Colkesen, Yucel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10017398/
https://www.ncbi.nlm.nih.gov/pubmed/36937632
http://dx.doi.org/10.1002/ccr3.7116
_version_ 1784907573926821888
author Colkesen, Yucel
author_facet Colkesen, Yucel
author_sort Colkesen, Yucel
collection PubMed
description Pulmonary embolism has a high frequency in COVID‐19 patients admitted to the intensive care unit. Low level of fibrinolysis is one of the asserted contributors to a prothrombotic state in COVID‐19. Thrombotic coagulopathy is mostly encountered as diffuse pulmonary thrombi. Diffuse pulmonary microemboli was treated successfully with reduced dose thrombolysis.
format Online
Article
Text
id pubmed-10017398
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-100173982023-03-17 Systemic reduced‐dose alteplase for diffuse pulmonary thrombi in a COVID‐19 patient Colkesen, Yucel Clin Case Rep Case Report Pulmonary embolism has a high frequency in COVID‐19 patients admitted to the intensive care unit. Low level of fibrinolysis is one of the asserted contributors to a prothrombotic state in COVID‐19. Thrombotic coagulopathy is mostly encountered as diffuse pulmonary thrombi. Diffuse pulmonary microemboli was treated successfully with reduced dose thrombolysis. John Wiley and Sons Inc. 2023-03-15 /pmc/articles/PMC10017398/ /pubmed/36937632 http://dx.doi.org/10.1002/ccr3.7116 Text en © 2023 The Author. Clinical Case Reports published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Case Report
Colkesen, Yucel
Systemic reduced‐dose alteplase for diffuse pulmonary thrombi in a COVID‐19 patient
title Systemic reduced‐dose alteplase for diffuse pulmonary thrombi in a COVID‐19 patient
title_full Systemic reduced‐dose alteplase for diffuse pulmonary thrombi in a COVID‐19 patient
title_fullStr Systemic reduced‐dose alteplase for diffuse pulmonary thrombi in a COVID‐19 patient
title_full_unstemmed Systemic reduced‐dose alteplase for diffuse pulmonary thrombi in a COVID‐19 patient
title_short Systemic reduced‐dose alteplase for diffuse pulmonary thrombi in a COVID‐19 patient
title_sort systemic reduced‐dose alteplase for diffuse pulmonary thrombi in a covid‐19 patient
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10017398/
https://www.ncbi.nlm.nih.gov/pubmed/36937632
http://dx.doi.org/10.1002/ccr3.7116
work_keys_str_mv AT colkesenyucel systemicreduceddosealteplasefordiffusepulmonarythrombiinacovid19patient

Ejemplares similares